485 related articles for article (PubMed ID: 25676488)
21. Innovation in oncology clinical trial design.
Verweij J; Hendriks HR; Zwierzina H;
Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
[TBL] [Abstract][Full Text] [Related]
22. [Recent progress of clinical trials in urologic oncology].
Hinotsu S
Gan To Kagaku Ryoho; 2006 Feb; 33(2):188-92. PubMed ID: 16484854
[TBL] [Abstract][Full Text] [Related]
23. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
24. An Escalation for Bivariate Binary Endpoints Controlling the Risk of Overtoxicity (EBE-CRO): Managing Efficacy and Toxicity in Early Oncology Clinical Trials.
Colin P; Delattre M; Minini P; Micallef S
J Biopharm Stat; 2017; 27(6):1054-1072. PubMed ID: 28375746
[TBL] [Abstract][Full Text] [Related]
25. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
26. Trend toward noninferiority trials may mean more difficult interpretation of trial results.
Tuma RS
J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926
[No Abstract] [Full Text] [Related]
27. Assessing tumor-related signs and symptoms to support cancer drug approval.
Williams G; Pazdur R; Temple R
J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497
[TBL] [Abstract][Full Text] [Related]
28. End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article.
Wildiers H; Mauer M; Pallis A; Hurria A; Mohile SG; Luciani A; Curigliano G; Extermann M; Lichtman SM; Ballman K; Cohen HJ; Muss H; Wedding U
J Clin Oncol; 2013 Oct; 31(29):3711-8. PubMed ID: 24019549
[TBL] [Abstract][Full Text] [Related]
29. Endpoints for assessing drug activity in clinical trials.
Pazdur R
Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
[TBL] [Abstract][Full Text] [Related]
30. Gestational trophoblastic neoplasia and evidence-based medicine.
Kohorn EI
J Reprod Med; 2002 Jun; 47(6):427-32. PubMed ID: 12092010
[TBL] [Abstract][Full Text] [Related]
31. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
32. Evidence-based medicine: the design and interpretation of noninferiority clinical trials in veterinary medicine.
Freise KJ; Lin TL; Fan TM; Recta V; Clark TP
J Vet Intern Med; 2013; 27(6):1305-17. PubMed ID: 24128266
[TBL] [Abstract][Full Text] [Related]
33. Clinical and outcome research in oncology. The need for integration.
Apolone G
Health Qual Life Outcomes; 2003 Apr; 1():3. PubMed ID: 12713667
[TBL] [Abstract][Full Text] [Related]
34. The importance of quality-of-life endpoints in clinical trials to the practicing oncologist.
Passik SD; Kirsh KL
Hematol Oncol Clin North Am; 2000 Aug; 14(4):877-86. PubMed ID: 10949778
[TBL] [Abstract][Full Text] [Related]
35. [Foreward].
Ehninger G; Overkamp F; Freund M;
Onkologie; 2013; 36 Suppl 2():1. PubMed ID: 23549029
[No Abstract] [Full Text] [Related]
36. Rare cancer trial design: lessons from FDA approvals.
Gaddipati H; Liu K; Pariser A; Pazdur R
Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
[TBL] [Abstract][Full Text] [Related]
37. Phase 0 clinical trials in oncology: an exploratory methodology for constructing a study with patients undergoing surgery for metastatic disease.
Pocard M; Soria JC; Aldaz-Carroll L; Bellet D
J Clin Oncol; 2010 Oct; 28(30):4551-3. PubMed ID: 20837954
[No Abstract] [Full Text] [Related]
38. Demystify statistical significance--time to move on from the p value to bayesian analysis.
Lee JJ
J Natl Cancer Inst; 2011 Jan; 103(1):2-3. PubMed ID: 21131578
[No Abstract] [Full Text] [Related]
39. Evaluating patient-centered outcomes in the randomized controlled trial and beyond: informing the future with lessons from the past.
Booth CM
Clin Cancer Res; 2010 Dec; 16(24):5963-71. PubMed ID: 21169249
[TBL] [Abstract][Full Text] [Related]
40. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
